5th annual meeting of the IRN iGPCRnet in Barcelona - 7-9th July 2025

DAY 1: July 7th

13.00h

Registration and Welcome

Session 1: Physiology of disease                                                            Chair: Amadeu Llebaria

14.00h

PT1:  Ferdinando Nicoletti (Mediterranean Neurological Institute, IRCCS Neuromed, Pozzilli,, IT)

The potential of photopharmacology for mGlu receptors: from mapping pain neuraxis to enhancing recovery after stroke

15.00h

OP01   Dayana Abboud (University of Liège, BE)

GPR101 modulates body weight and food intake through specific population of neurons

15.15

OP02   Paula Álvarez-Montoya (University of Barcelona, ES)
Gpr37 modulation of dopaminergic signaling: a molecular insight into schizophrenia pathophysiology

15.30h

Industrial short talks (sponsors)

16.00

Coffee break

Session 2: Context-dependent signalling                                                   Chair: Francisco Ciruela

16.30h

KT1:     Meritxell Canals (University of Nottingham, UK)
Delineating molecular and cellular determinants of μ-opioid receptor – β-arrestin2 interactions

17.15h

OC1:    Mikel Garcia Marcos (Boston University, US)

The secret life of G proteins

17.35h

OP03:  Michela Di Michele (Institut des Biomolécules Max Mousseron, Montpellier, FR)

Lipid environment modulates the scramblase activity of the ghrelin receptor

1.50h

OP04:  Shanlin Rao (University of Cambridge, UK)

A systems view of GPCR signalling pathway (re)wiring: Implications for pharmacology

18.05h

Poster session 1  (PP001-PP040)

19.25h

Dinner

DAY2: July 8th

Session 3: Subcellular localised signalling and receptor internalisation                 Chair: Rebeca Díez-Alarcia

8.45h

OC2:    Anna Aragay (Molecular Biology Institute of Barcelona - CSIC, ES)

Gq regulation of organelle contacts and dynamics

9.05h

OP05:   Raphael S. Haider (University of Nottingham, UK)

Sketching subcellular maps of GPCR signaling complex formation and regulatory routes in the context of pain - are there pro-nociceptive arrestin conformational states?

9.20h

OP06   Julie Dam (Institut Cochin, Paris, FR)
Correcting GLP-1R mutants from human carriers with a potent pharmacological chaperone

9.35h

OP07   Marta Cimadevila (Institut de Génomique Fonctionnelle, Montpellier, FR)

Non canonical internalization properties of mGlu3

9.50h

OP08:  Sergi Bravo (University of Bonn, DE)

Nature’s Blueprint for Hyperefficient GPCR Internalisation : Leveraging Signaling Suppression and Receptor Endocytosis

10.05h

Coffee break

Session 4: GPCR Interacting proteins and oligomerisation                                  Chair: Gemma Navarro

10.35h

KT2:      Federico Mayor (Institute for Molecular Biology UAM-CSIC, Madrid, ES)

GRK2 interactomes in cellular signalling and disease

11.20h

OP09:  Céline Delaitre (University of Copenhagen, DK)

Regulation of GPCR oligomerization revealed by high-throughput quantitative fluorescence imaging

11.35h

OP10   Marc Ciruela-Jardí (universitat Autònoma de Barcelona, ES)

Distinct heteromeric partners modulate (S)-Methadone efficacy in MOR

11.50h

Poster session 2 (PP041-PP80)

13.10h

Lunch

Session 5: New methodologies and molecular tools to study GPCR activity                          Chair: Xavier Rovira

14.10h KT2:     Rob Leurs (Vrije Universiteit Amsterdam, NL)

Photopharmacology: towards new tools to unravel GPCR pharmacolog

15.10h  OP12   Chia-Yang Lin (University of Nottingham, UK)

Ligand-directed labelling probes for covalent labelling of A₁ Adenosine Receptors

15.25 OP13   Iulia Bodnariuc (University of Utrecht , NL)

Methodology to study GPCRs in the native membrane environment: an in-cell solid-state NMR approach

15.40h Coffee break

Session 6: GPCR research in the industry                                                                 Chair: TBD

16.10h  KT4:     Dominik Schelshorn and Anaëlle Dumazer (Neurosterix, Geneva, CH)

Beyond orthosteric binding in GPCR research: innovative assays for allosteric modulator drug discovery

16.55h  OC3:    Elodie Dupuis (Revvity, Codolet, FR)

New fluorescent detection modalities to investigate GPCRs signaling

17.15h OC6:    Lawrence Welch (Nuclera, Cambridge, UK)

Producing assay-ready, purified, stable membrane proteins in under 48 hours

17.35h General Assembly iGPCRnet

18.05h Poster Session 3 (PP081-PP120)

19.25h Dinner

DAY 3: July 9th

Session 7: Molecular insights from structural biology and modelling                   Chair: Javier Garcia-Nafría

8.45h    KT5: Jörg Standfuss (Paul Scherrer Institute, Villigen, CH)    

Tracking ligand-GPCR interaction dynamics by time-resolved serial     crystallography

9.30h    OC7: Guillaume Lebon (Inst. Functional Genomics, Montpellier, FR)    

Conformational; diversity on class C GPCR positive allosteric modulation

9.50h    OP14: Jana Selent (Hosp. del Mar Medical Research Inst., Barcelona, ES)    

Expanding the conformational space of the 3D GPCRome

10.05h    OP15: Masha Niv (The Hebrew University of Jerusalem, IL)    

Bitter Taste GPCRs in the Age of CryoEM and LLMs

10.20h    OP16: Arisbel B. Gondin (Monash University, Parkville, AU)    

Structure-guided design of allosteric modulators at the δ-Opioid Receptor

10.35 Coffee break

11.05h    OC5: Maria Majellaro (Celtarys, Santiago de Compostela, ES)    

A game-changing technology to Illuminate GPCR pharmacology: accelerating hit discovery & optimization

11.25h    OC4: Martha Sommer (ISAR Bioscience, München, DE)    

An Arresting Perspective on GPCR Signal Transduction

11.55h    OP17: Pierre-André Lafon (Inst. Functional Genomics, Montpellier, FR)    

Nanobody activator of mGlu2 receptor accelerates amyloidogenesis in Alzheimer’s disease

12:10h    OP18: Pierre Couvineau (Inst. Functional Genomics, Montpellier, FR)    

Functional selectivity of prototypical class A GPCRs : A journey from in silico to in vivo

12:25h    PT2: Francisco Ciruela (University of Barcelona, ES)    

In vivo GPCR Photopharmacology: Towards Therapeutics?

13.25h    Conclusion and prizes